Testing a mouth bacteria treatment for PSC
Part of Digestive system clinical trials.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 76 years old.
- Have PSC without severe liver damage complications.
- No antibiotics (except vancomycin) in the last 3 months.
- No cirrhosis, liver transplant, or severe liver disease.
- No active cancer, hepatitis, or other bile duct diseases.
- Must stop other experimental PSC treatments 3 months before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.